carfilzomib / Generic mfg.  >>  Phase 1
Welcome,         Profile    Billing    Logout  

23 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
carfilzomib / Generic mfg.
ACTRN12621001458820: Safety and Tolerability of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib

Not yet recruiting
1
36
 
South Western Sydney Local Health District, South Western Sydney Local Health District
Cancer, Myeloma
 
 
ACTRN12621001458820p: Safety and Tolerability of Hydroxychloroquine in Participants with Multiple Myeloma and Partial Response or Less to Carfilzomib

Not yet recruiting
1
36
 
South Western Sydney Local Health District, South Western Sydney Local Health District
Cancer; Myeloma
 
 
EQUULEUS, NCT01998971: A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

Checkmark Subgroup analysis of MMY1001 at ASCO 2018 [screenshot]
Jun 2018 - Jun 2018: Subgroup analysis of MMY1001 at ASCO 2018 [screenshot]
Checkmark In combination with KRd for NDMM at ASH 2017 [screenshot]
Dec 2017 - Dec 2017: In combination with KRd for NDMM at ASH 2017 [screenshot]
Checkmark In combination with Kd for relapsed MM at ASH 2017 [screenshot]
More
Completed
1
240
Europe, US
Daratumumab, Velcade, Pomalidomide, Dexamethasone, Melphalan, Prednisone, Thalidomide, Diphenhydramine, Acetaminophen, Carfilzomib, Lenalidomide, Montelukast
Janssen Research & Development, LLC
Multiple Myeloma
01/19
01/24
NCT03273829: Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed or Refractory Solid Tumors and Leukemias

Recruiting
1
7
US, Canada
Cyclophosphamide, Etoposide, Carfilzomib
Memorial Sloan Kettering Cancer Center
Leukemia, Pediatric Leukemia, Pediatric Solid Tumor
08/19
08/19
NCT01301807: Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma

Completed
1
63
US
Carfilzomib, Kyprolis, PR-171, Panobinostat, Faridak, Farydak, LBH589
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
11/19
11/19
NCT01959698: Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Active, not recruiting
1
29
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Carfilzomib, Kyprolis, PR-171, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Pharmacological Study, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, RTXM83
Roswell Park Cancer Institute, National Cancer Institute (NCI), Amgen
CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Stage I Diffuse Large B-Cell Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma
06/20
06/25
NCT02101944: Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Dec 2015 - Dec 2015: From pilot clinical trial of combination with Reolysin for multiple myeloma at ASH 2015
Completed
1
12
US
Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Laboratory Biomarker Analysis, Pelareorep, PO BB0209, PO-BB0209, Reolysin, Reovirus Serotype 3, Wild-type Reovirus
National Cancer Institute (NCI)
Anemia, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
05/21
05/24
POE14-01, NCT02512926: Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children

Completed
1
4
Canada, US
Carfilzomib, Cyclophosphamide, Etoposide
Stanford University, Pediatric Oncology Experimental Therapeutics Investigators' Consortium, Amgen
Relapsed Solid Tumors, Refractory Solid Tumors, Relapsed Leukemia, Refractory Leukemia
08/21
11/23
NCT03605719: Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Checkmark Updated results
Dec 2018 - Dec 2018: Updated results
Completed
1
23
US
Carfilzomib, Kyprolis, PR-171, Dexamethasone, Decadron, Hexadrol, Ozurdex, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Pelareorep, Reolysin, Wild-type Reovirus
Emory University, Bristol-Myers Squibb, Oncolytics Biotech, University of Utah, City of Hope Medical Center, Phylogeny, National Cancer Institute (NCI), National Institutes of Health (NIH)
Recurrent Plasma Cell Myeloma
10/22
10/22
CarMob, NCT03909412: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Suspended
1
18
US
Carfilzomib, Kyprolis, Cyclophosphamide, Cytoxan, Dexamethasone, Decadron, Granulocyte Colony-Stimulating Factor, G-CSF, Filgrastim, Neupogen
Hackensack Meridian Health, Amgen
Multiple Myeloma
12/24
12/24
NCT03031730: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Recruiting
1
40
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Dexamethasone Sodium Phosphate, Cebedex, Corson, Dalalone, Decaject, Dekasol LA, Dexacen, Dexamethasone Sodium Phosphates, Dexasone, Dezone, ReadySharp Dexamethasone, Soludecadron, Solurex, Topidex, Echocardiography, EC, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232
National Cancer Institute (NCI)
Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
12/24
12/24
NCT03798678: CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

Active, not recruiting
1
36
US
Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Telaglenastat Hydrochloride, CB-839 HCl, Glutaminase Inhibitor CB-839 Hydrochloride
National Cancer Institute (NCI)
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
01/25
01/25
TTI-622-01, NCT03530683: A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma

Checkmark First patient dosed in combination with azacitidine for TP53-mutated AML
Aug 2021 - Aug 2021: First patient dosed in combination with azacitidine for TP53-mutated AML
Checkmark Data from trial for lymphoma
Apr 2021 - Apr 2021: Data from trial for lymphoma
Active, not recruiting
1
177
US
Maplirpacept (PF-07901801), SIRPα-IgG4 Fc, TTI-622, Azacitidine, VIDAZA, Venetoclax, VENCLEXTA, Carfilzomib, KYPROLIS, Dexamethasone, Anti-CD20 Targeting agent, Ruxience or Rituxan, Isatuximab, Sarclisa
Pfizer
Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
09/24
09/24
NCT04813653: Cyclosporine in Combination With Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Refractory to Carfilzomib and High Expression of PPIA Gene in Myeloma Cells

Recruiting
1
10
RoW
cyclosporine in combination with carfilzomib and dexamethasone
Tel-Aviv Sourasky Medical Center, Weizmann Institute of Science
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
04/24
05/24
NCT06249282: Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
1
15
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carfilzomib, Carfilnat, CFZ, Kyprolis, PR-171, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Sotorasib, AMG 510, AMG-510, AMG510, Lumakras, Lumykras
City of Hope Medical Center, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
03/26
03/26
NCT02303821 / 2014-001633-84: Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

Active, not recruiting
1
130
Europe, Canada, US, RoW
Carfilzomib, PR-171, PR171, Kyprolis® (carfilzomib) for Injection, Dexamethasone, Mitoxantrone, PEG-asparaginase, Vincristine, Intrathecal (IT) Methotrexate, Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate), 6-Mercaptopurine, Cyclophosphamide, Cytarabine, Daunorubicin
Amgen, Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) - Study Design & Execution Collaborator, Innovative Therapies For Children with Cancer Consortium
Acute Lymphoblastic Leukemia (ALL)
07/24
07/24
SINE, NCT02199665: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Checkmark Selinexor in combination with carfilzomib and dexamethasone for relapsed/refractory MM
Dec 2015 - Dec 2015: Selinexor in combination with carfilzomib and dexamethasone for relapsed/refractory MM
Recruiting
1
100
US
selinexor, CRM1 nuclear export inhibitor KPT-330, KPT-330, selective inhibitor of nuclear export KPT-330, SINE KPT-330, carfilzomib, Kyprolis, PR-171, dexamethasone, Aeroseb-Dex, Decaderm, Decadron, DM, DXM
University of Chicago, National Cancer Institute (NCI)
Refractory Multiple Myeloma
07/24
12/24
NCT02332850: Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
83
Canada, US
Isatuximab, SAR 650984, Carfilzomib, Kyprolis, PR-171, Dexamethasone, Orgadrone, Spersadex, Visumetazone
Thomas Martin, MD, Amgen, Sanofi
Multiple Myeloma
12/24
12/24
MonumenTAL-2, NCT05050097: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Recruiting
1
182
Europe, US, RoW
Talquetamab, JNJ-64407564, Carfilzomib, Daratumumab SC, Lenalidomide, Pomalidomide
Janssen Research & Development, LLC
Multiple Myeloma
07/25
10/25
NCT03432741: Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

Suspended
1
39
US
Belinostat, Beleodaq, PXD 101, PXD101, Carfilzomib, Kyprolis, PR-171, Copanlisib Hydrochloride, 5-Pyrimidinecarboxamide, 2-Amino-N-(2,3-dihydro-7-methoxy-8-(3-(4-morpholinyl)propoxy)imidazo(1,2-C)quinazolin-5-yl)-, Hydrochloride (1:2), Aliqopa, BAY 80-6946 Dihydrochloride, BAY-80-6946 Dihydrochloride, Copanlisib Dihydrochloride, Daratumumab, Anti-CD38 Monoclonal Antibody, Darzalex, HuMax-CD38, JNJ-54767414, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Romidepsin, Antibiotic FR 901228, Depsipeptide, FK228, FR901228, Istodax, N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic, Saline, ISOTONIC SODIUM CHLORIDE SOLUTION, Sodium Chloride 0.9%, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, Kanjinti, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab Biosimilar SIBP-01, Trastuzumab-anns, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-qyyp, Trazimera
Mayo Clinic, National Cancer Institute (NCI)
Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
04/25
05/26
iinnovate-2, NCT05556616: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Active, not recruiting
1
120
Europe, US, RoW
Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide
Takeda
Multiple Myeloma
01/24
06/24
MagnetisMM-20, NCT05675449: A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma

Recruiting
1
90
US, RoW
Elranatamab, PF-06863135, Carfilzomib, Kyprolis, Maplirpacept, PF-07901801, TTI-622
Pfizer
Multiple Myeloma
05/26
03/28
LINKER-MM2, NCT05137054: A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Recruiting
1
317
Europe, US
Linvoseltamab, REGN5458, Daratumumab, Darzalex®; Darzalex Faspro™, Carfilzomib, Kyprolis®, Lenalidomide, Revlimid®, Bortezomib, Velcade®, Pomalidomide, Imnovid, Pomalyst®, Isatuximab, Sarclisa®, Fianlimab, REGN3767, Cemiplimab, LIBTAYO, Nirogacestat, PF-03084014
Regeneron Pharmaceuticals
Multiple Myeloma
03/27
01/33

Download Options